CERNER CORPORATION

CERN
End-of-day quote. End-of-day quote  - 06/07
94.92USD -0.05%

Cerner Corporation, Elligo Health Research and Freenome Collaborate to Enable Clinical Trial Through the Learning Health Network to Help Advance Early Cancer Detection

05/18/2022 | 02:15pm
Cerner Corporation, Elligo Health Research and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. Together they will be using the research-activated network of health systems, real-world data (RWD) and multiomics technology, developed by Freenome, with the goal to help accelerate early cancer detection. This will be one of the first cancer screening trials available to Cerner's rapidly growing Learning Health Network (LHN). Trial participation will help LHN members bring innovative cancer prevention testing to the communities they serve – no matter their size or where they are located. Freenome, Cerner and Elligo will team up to use RWD to drive the Sanderson Study, an upcoming clinical trial to detect multiple types of cancer which is IRB approved and uses new multiomics technology. Elligo Health Research will work with LHN members to accelerate site activation and enroll a large volume of diverse patients much faster than traditional recruitment models. Spanning the U.S., the collaboration will enable diverse patient participation, across a wide variety of demographics, socio-economic factors and all sizes of communities.
© S&P Capital IQ 2022
Copier lien
All news about CERNER CORPORATION
06/10
06/08
06/08
06/08
06/08